United States News Todas as matérias

PDD Holdings (NASDAQ:PDD) reported an 11% increase in revenue for the first quarter of 2026, driven by growth in its transaction services division.

The U.S. Food and Drug Administration has extended its review period for AstraZeneca's (NASDAQ:AZN) New Drug Application for camizestrant, delaying a final decision on the advanced breast cancer treatment.

Kingsoft Cloud Holdings (NASDAQ:KC) reported a 37.2% year-over-year surge in total revenue for the first quarter of 2026, driven by expanding artificial intelligence demand and deeper penetration into enterprise accounts.

ChipMOS TECHNOLOGIES (NASDAQ:IMOS) announced that its shareholders have officially approved a cash dividend distribution from the company’s capital surplus during its Annual General Meeting held on May 26, 2026.

Bank of Montreal (NYSE:BMO) has released its financial results for the second quarter of 2026, posting a reported net income of $2.63 billion.

Colliers (NASDAQ:CIGI) has officially closed its acquisition of Ayesa Engineering, the engineering division of the Seville-based Ayesa Group, marking a significant expansion of the global real estate and investment management firm's technical capabilities.

Sociedad Química y Minera de Chile (NYSE:SQM) reported a sharp rebound in its first-quarter financial results for 2026, driven by an acceleration in electric vehicle battery materials demand that led the producer to raise its full-year delivery guidance.

Aligos Therapeutics (NASDAQ:ALGS) presented a series of clinical and preclinical data packages spanning its liver disease and viral portfolios, highlighting long-term tracking data from its lead drug candidate alongside several pipeline assets.

Gilead Sciences (NASDAQ:GILD) released new results from a post hoc analysis of its open-label Phase 3 ASSURE study, demonstrating that its approved drug Livdelzi (seladelpar) achieved high and sustained rates of normalization in a key biomarker of liver disease progression.

Precision BioSciences (NASDAQ:DTIL) unveiled late-breaking clinical data from its ongoing Phase 1/2a ELIMINATE-B trial, delivering what it characterizes as the first-ever human biopsy evidence of a therapeutic agent successfully eliminating and inactivating the root genetic reservoir of chronic hepatitis B.

Silvercorp Metals (NYSE:SVM reported record revenue for its full fiscal year 2026, driven by a dramatic rally in global silver prices that generated substantial operating cash flow and offset heavy non-cash accounting adjustments.

Hafnia (NYSE:HAFN) reported a near-tripling of its first-quarter net profit for 2026, capitalized on a robust global product tanker market that drove sharp increases in average daily charter rates and expanded operational cash generation.

DigitalBridge Group (NYSE:DBRG) agreed to acquire ArcLight Capital Partners for up to $1.05 billion, bridging the gap between data center operators and the electric grid as artificial intelligence applications trigger unprecedented demands for power.

PodcastOne (NASDAQ:PODC) raised its financial projections for the full fiscal year 2026, driven by an optimized capital structure and preliminary steps to monetize its historical media library through artificial intelligence data-licensing agreements.

SunCar Technology Group (NASDAQ:SDA) reported an expansion in first-quarter revenue and sustained bottom-line profitability, driven by accelerating consumer demand for electric vehicle insurance and broader commercial partnerships with major digital and automotive brands across China.

Israel Corp. (NASDAQ:NOAP) reported a substantial increase in its first-quarter net profit, driven by expanding returns from its core chemicals subsidiary and an investment windfall stemming from a recent food-technology listing.

Merck (NYSE:MRK) announced that its board of directors has formally declared a quarterly dividend of $0.85 per share.

Kyivstar Group (NASDAQ:KYIV) announced the acquisition of six solar power plants in Ukraine’s Lviv region for a total consideration of UAH 3.6 billion (approximately $80.8 million), accelerating the telecommunication firm’s vertical integration into sovereign power generation to mitigate localized infrastructure risks.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) unveiled new clinical data expanding the medical profile of plozasiran, its approved RNA interference (RNAi) therapeutic, demonstrating that the drug can be administered to patients suffering from moderate-to-severe renal impairment or moderate hepatic impairment without necessitating a reduction in dose.

Shares of Micron Technology (NASDAQ:MU) surged to an all-time intraday high following a dramatic price target increase from UBS, which argued that the artificial intelligence infrastructure buildout has permanently altered the financial predictability and valuation framework of the memory chip industry.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) released updated Phase 1/2 clinical data for its experimental antibody-drug conjugate, CRB-701, demonstrating therapeutic activity in patients with pretreated, human papillomavirus (HPV)-associated solid tumors that express high levels of the Nectin-4 protein.

Performance Shipping (NASDAQ:PSHG) reported a 59% increase in first-quarter revenue for 2026, driven by a larger operational fleet and stronger charter rates that accelerated the company's operating cash generation.

Dyne Therapeutics (NASDAQ:DYN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking conditional marketing clearance for z-rostudirsen, its investigational treatment targeting a specific subset of patients with Duchenne muscular dystrophy (DMD).

Virax Biolabs Group (NASDAQ:VRAX) announced positive preliminary performance metrics from an early pilot dataset for ViraxImmune™, its proprietary blood-based diagnostic test under development for Long COVID and related post-acute infection syndromes (PAIS).